Published in J Endocrinol on October 01, 1999
Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials. Menopause (2011) 1.56
Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment. Menopause (2015) 1.43
Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochim Biophys Acta (2009) 1.17
Acute modulation of adipose tissue lipolysis by intravenous estrogens. Obesity (Silver Spring) (2006) 0.97
Soy isoflavones increase preprandial peptide YY (PYY), but have no effect on ghrelin and body weight in healthy postmenopausal women. J Negat Results Biomed (2006) 0.82
Estrogen or raloxifene during postmenopausal weight loss: adiposity and cardiometabolic outcomes. Obesity (Silver Spring) (2013) 0.79
Is there evidence that estrogen therapy promotes weight maintenance via effects on leptin? Menopause (2014) 0.79
Menopause, obesity and inflammation: interactive risk factors for Alzheimer's disease. Front Aging Neurosci (2015) 0.78
Regulation of energy expenditure by estradiol in premenopausal women. J Appl Physiol (1985) (2015) 0.77
A meta-analysis of reference values of leptin concentration in healthy postmenopausal women. PLoS One (2013) 0.76
Menopause care for obese and diabetic women. Facts Views Vis Obgyn (2009) 0.75
Preventive effects of raloxifene treatment on agerelated weight loss in postmenopausal women. J Bone Miner Metab (2016) 0.75
Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology (2001) 3.00
Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res (2001) 2.89
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int (2007) 2.46
Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int (2006) 2.33
Risk of fractures in patients with multiple sclerosis: a population-based cohort study. Neurology (2012) 2.25
Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int (2005) 2.23
Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond) (2005) 2.18
Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev (2005) 2.15
Fracture rates and risk factors for fractures in patients with spinal cord injury. Spinal Cord (1998) 2.07
Heart failure in patients treated with bisphosphonates. J Intern Med (2013) 2.00
Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM. Diabetes (1997) 2.00
Vitamin D status and its adequacy in healthy Danish perimenopausal women: relationships to dietary intake, sun exposure and serum parathyroid hormone. Br J Nutr (2001) 1.84
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia (2005) 1.79
Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int (2008) 1.78
Associations between different anthropometric measurements of fatness and metabolic risk parameters in non-obese, healthy, middle-aged men. Int J Obes Relat Metab Disord (1995) 1.77
Fracture risk associated with the use of morphine and opiates. J Intern Med (2006) 1.71
Cerebrospinal fluid adrenaline and noradrenaline in depressed patients. Acta Psychiatr Scand (1980) 1.65
Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res (1993) 1.57
Identification of oestrogen receptors and oestrogen receptor mRNA in human adipose tissue. Eur J Clin Invest (1996) 1.53
Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. Clin Sci (Lond) (1979) 1.49
Mean serum concentration of vitamin D-binding protein (Gc globulin) is related to the Gc phenotype in women. Clin Chem (2001) 1.48
Stereological considerations concerning the measurement of individual osteoid seams and resorption cavities. Bone Miner (1994) 1.47
Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ (2000) 1.47
Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest (2002) 1.46
Autosomal dominant osteopetrosis. Clin Orthop Relat Res (1993) 1.44
Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry (2000) 1.43
Stroke in relation to use of raloxifene and other drugs against osteoporosis. Osteoporos Int (2010) 1.42
Familial isolated primary hyperparathyroidism. Clin Endocrinol (Oxf) (1994) 1.42
Clopidogrel and the risk of osteoporotic fractures: a nationwide cohort study. J Intern Med (2012) 1.41
Polymorphisms of muscle genes are associated with bone mass and incident osteoporotic fractures in Caucasians. Calcif Tissue Int (2013) 1.40
[Costs of different intervention strategies to prevent hip fractures]. Ugeskr Laeger (1999) 1.39
Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone Gla-protein. Calcif Tissue Int (1989) 1.39
Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int (2006) 1.39
[Obesity. New therapeutic perspectives]. Ugeskr Laeger (1996) 1.38
Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut (2000) 1.33
Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006. Osteoporos Int (2009) 1.33
Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) (2005) 1.30
Vitamin D and its binding protein Gc: long-term variability in peri- and postmenopausal women with and without hormone replacement therapy. Scand J Clin Lab Invest (2006) 1.29
The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab (1988) 1.29
Antidepressant medications and osteoporosis. Bone (2012) 1.28
Fracture risk in patients treated for hyperthyroidism. Thyroid (2000) 1.25
Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals. Bone (1990) 1.23
Hypocholesterolaemic effect of a new fermented milk product in healthy middle-aged men. Eur J Clin Nutr (1995) 1.23
Lumbar vertebral body compressive strength evaluated by dual-energy X-ray absorptiometry, quantitative computed tomography, and ashing. Bone (1999) 1.22
Regional differences in triglyceride breakdown in human adipose tissue: effects of catecholamines, insulin, and prostaglandin E2. Metabolism (1991) 1.21
Age- and sex-related changes in iliac cortical bone mass and remodeling. Bone (1994) 1.19
Fractures in patients with primary idiopathic hypothyroidism. Thyroid (2000) 1.17
Biomechanical competence of vertebral trabecular bone in relation to ash density and age in normal individuals. Bone (1987) 1.17
Histomorphometric analysis of normal bone from the iliac crest. Acta Pathol Microbiol Scand A (1978) 1.16
Normal vertebral body size and compressive strength: relations to age and to vertebral and iliac trabecular bone compressive strength. Bone (1986) 1.16
Effects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels - results from a randomized trial. Eur J Intern Med (2013) 1.14
Vitamin D insufficiency in Greenlanders on a westernized fare: ethnic differences in calcitropic hormones between Greenlanders and Danes. Calcif Tissue Int (2003) 1.14
Demonstration of estrogen receptor subtypes alpha and beta in human adipose tissue: influences of adipose cell differentiation and fat depot localization. Mol Cell Endocrinol (2001) 1.14
Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition. Metab Bone Dis Relat Res (1984) 1.14
Fracture risk is increased in epilepsy. Acta Neurol Scand (1999) 1.13
Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab (2001) 1.12
Tetracycline double-labeling of iliac trabecular bone in 41 normal adults. Calcif Tissue Res (1978) 1.12
Age-related changes in the biochemical properties of human cancellous bone collagen: relationship to bone strength. Calcif Tissue Int (1999) 1.12
Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int (2013) 1.11
Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int J Obes (Lond) (2010) 1.11
Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. Bone (1996) 1.11
Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. Bone (1999) 1.10
Trabecular bone remodeling and balance in primary hyperparathyroidism. Bone (1986) 1.10
Effects of 25OHD concentrations on chances of pregnancy and pregnancy outcomes: a cohort study in healthy Danish women. Eur J Clin Nutr (2012) 1.09
Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int (2011) 1.08
Lithium treatment regimen and renal water handling: the significance of dosage pattern and tablet type examined through comparison of results from two clinics with different treatment regimens. Psychopharmacology (Berl) (1982) 1.08
Clinically significant side effects of lithium treatment. A survey of 237 patients in long-term treatment. Acta Psychiatr Scand (1980) 1.08
Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am J Physiol Endocrinol Metab (2003) 1.07
Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner (1994) 1.07
A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone (1989) 1.06
Discordance between changes in bone mineral density measured at different skeletal sites in perimenopausal women--implications for assessment of bone loss and response to therapy: The Danish Osteoporosis Prevention Study. J Bone Miner Res (2001) 1.06
Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int (2006) 1.06
Serum lithium concentrations around the clock with different treatment regimens and the diurnal variation of the renal lithium clearance. Acta Psychiatr Scand (1981) 1.06
Mortality in Cushing's syndrome: a systematic review and meta-analysis. Eur J Intern Med (2011) 1.06
Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus. Diabetologia (2006) 1.06
Reduced relative risk of fractures among users of lithium. Calcif Tissue Int (2005) 1.05
Regulation of UCP1, UCP2, and UCP3 mRNA expression in brown adipose tissue, white adipose tissue, and skeletal muscle in rats by estrogen. Biochem Biophys Res Commun (2001) 1.04
Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults. J Clin Endocrinol Metab (2011) 1.03
Effects of in vivo estrogen treatment on adipose tissue metabolism and nuclear estrogen receptor binding in isolated rat adipocytes. Mol Cell Endocrinol (1992) 1.03
An evaluation of the quantitative parameters applied in bone histology. Acta Pathol Microbiol Scand A (1978) 1.02
Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry (1998) 1.02
Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res (2003) 1.02